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Summary statement 
We have uncoupled the relationship between C9orf72 linked motor neuron disease 
pathologies by expressing GGGGCC repeat expansions in mice. 
 
Abstract 
Intronic GGGGCC repeat expansions in C9orf72 are the most common genetic cause of 
amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Two major 
pathologies stemming from the hexanucleotide RNA expansions (HREs) have been identified 
in postmortem tissue: intracellular RNA foci and repeat-associated non-ATG dependent (RAN) 
dipeptides, though it is unclear how these and other hallmarks of disease contribute to the 
pathophysiology of neuronal injury. Here we generated two novel lines of mice that 
overexpress either 10 or 102 G4C2 repeats mediated by adeno-associated virus (AAV) and 
characterized relevant pathology and disease-related behavioral phenotypes. Surprisingly, 
RNA foci pathology is independent of both repeat expansion size, RAN dipeptide formation, 
and behavioral phenotypes in our AAV-HRE treated mice. Similar levels of intracellular RNA 
foci developed in both lines of mice, but only mice expressing 102 repeats generated c9-RAN 
pathology, neuromuscular junction (NMJ) abnormalities, dispersal of the hippocampal CA1, 
enhanced apoptosis, and deficits in gait and cognition. Neither line of mice, however, showed 
extensive TAR DNA-binding protein 43 (TDP-43) pathology or neurodegeneration. Our data 
suggests that RNA foci pathology is not a good predictor of c9-RAN dipeptide formation, and 
that RAN dipeptides and NMJ dysfunction are drivers of c9-disease pathogenesis. These AAV-
mediated models of C9orf72 ALS/FTD will be useful tools for studying disease 
pathophysiology and developing new therapeutic approaches. 
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Introduction 
Hexanucleotide repeat expansions (HREs) in C9orf72 are regarded as the most common 
genetic cause of the progressive neurodegenerative diseases, amyotrophic lateral sclerosis 
(ALS) and frontotemporal dementia (FTD). ALS primarily affects motor neurons and leads to 
progressive failure of the neuromuscular system with muscle wasting and paralysis, while 
frontotemporal dementia (FTD) is caused by the degeneration of neurons in the frontal and 
temporal lobes leading to cognitive deficits. G4C2 repeat expansions in the first intron of 
C9orf72 are present in up to 40% of familial ALS and 25 % of familial FTD patients, and are 
also present in 5-20% of sporadic ALS patients (DeJesus-Hernandez et al., 2011, Renton et al., 
2011, Majounie et al., 2012, Renton et al., 2014). Normal healthy C9orf72 alleles contain 
between 2-30 repeats, while disease-associated alleles vary in size and can exceed several 
thousand HREs (DeJesus-Hernandez et al., 2011, Renton et al., 2011).  Three different 
pathological alterations providing clues to the etiology of C9orf72-related disease can be found 
in post-mortem tissue from patients with HREs: first, a reduction in all three mRNA transcripts 
generated from C9orf72, suggesting disease may arise by a loss-of-function mechanism 
(DeJesus-Hernandez et al., 2011, Belzil et al., 2013, Donnelly et al., 2013); second, formation 
of intracellular foci by aggregation of RNA expansions; and third, dipeptide repeat proteins 
(DPRs) which are generated from long expansions via repeat-associated non ATG-dependent 
(RAN) translation (Cooper-Knock et al., 2014, Schludi et al., 2015).   
 
Recent studies suggest that G4C2 expansions and DPRs may induce cell toxicity by 
sequestration of RNA binding proteins (Cooper-Knock et al., 2014, Lee et al., 2016) and 
disruption of nucleocytoplasmic transport (Zhang et al., 2015, Freibaum et al., 2015). Models 
designed to mimic either C9orf72 haploinsufficiency or toxic gain of function have been 
developed to identify the combination of factors inducing disease relevant pathology. While 
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C9orf72 knockout mice display motor and cognitive deficits along with heightened 
neuroinflammation, these mice do not exhibit any significant neuronal pathology, suggesting 
that a simple loss-of-function mechanism is unlikely to be the sole cause of C9orf72-linked 
neurodegeneration (Koppers et al., 2015, O'Rourke et al., 2016). Four different toxic gain-of-
function mouse models developed through expression of patient derived C9orf72 packaged in 
a bacterial artificial chromosome (BAC) consistently displayed intracellular RNA foci and 
DPRs in the CNS, though they differed in the generation of ALS/FTD disease phenotypes 
(Jiang et al., 2016, Liu et al., 2016, O'Rourke et al., 2015, Peters et al., 2015, Chew et al., 2015). 
There was no consensus between the four models as to what minimum HRE size leads to RNA 
foci formation, as some transgenic lines failed to form any c9-related pathology with even 100 
G4C2 repeats (Jiang et al., 2016), while others displayed robust c9RAN expression with as few 
as 37 repeats (Liu et al., 2016). In contrast to the BAC transgenic mice, which overexpress 
between 1-7 copies of C9orf72, acute AAV-mediated, actin-promoter-driven expression of 
(G4C2)66 in mice recapitulates ALS-like pathology and induces cognitive and behavioral 
deficits, without any flanking C9orf72 sequence (Chew et al., 2015).  
 
However in these mouse models, several fundamental questions regarding C9orf72 disease 
etiology remain unanswered: 1) Does a threshold concentration of RNA foci induce the 
formation of DPRs in vivo; 2) What neuropathological criteria are accurate predictors of 
behavioral deficits; 3) Which factors alter the balance between ALS and FTD phenotypes? To 
directly address these issues, we generated mice expressing HREs, utilizing AAV serotype 9 
(AAV9) to achieve an acute, widespread expression following cisterna magna delivery in 
postnatal day 1 (P1) pups. We used two lines of mice expressing HRE expansions (10 and 102 
repeats) to examine the effects of repeat length on disease etiology. We show that both AAV-
(G4C2)10  and AAV-(G4C2)102  repeats lead to the formation of a similar number of intranuclear 
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RNA foci in the CNS in vivo, but only (G4C2)102 transgenic mice generate DPRs, have Purkinje 
cell apoptosis, exhibit neuromuscular junction pathology, and display gait and cognitive 
deficits.           
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Materials and Methods 
 
Antibodies and Reagents 
Rabbit anti-AAV VP1, VP2, VP3 (1:800, #03-61084, American Res Prod, USA), rabbit anti-
NeuN (1:500, Cell Signalling (USA)- clone D3S3I), rabbit anti-GFAP (1:2000, Dako - Z0334), 
Rabbit anti-TDP-43 (1:500, Proteintech - catalog #18-280-1-AP), mouse anti-Calbindin 
(1:1000, Sigma C9848), mouse anti-p62 lck ligand (1:1000, BD Biosciences, clone 3,610833), 
rabbit anti-α-tubulin (1:5000, Abcam, cat #4074), rabbit-cleaved-caspase 3 (1:1000, Cell 
Signalling #9661), mouse anti-cleaved PARP (1:250, Cell Signalling #9548), mouse anti-
GAPDH (1:5000, Millipore), mouse anti-poly(Glycine-Alanine (GA), 1:500 for western blot; 
1:5000 for ICC, clone 5F2 (Mackenzie et al., 2013) kindly provided by Dieter Edbauer)  were 
used at the dilutions listed above.  
 
Cell lines and culture  
HEK 293T cells (Sigma) were maintained in growth media (GM) consisting of Dulbecco’s 
modified Eagle’s medium (DMEM, D5796, Sigma (USA)) supplemented with 10% foetal 
bovine serum (Sigma, USA), penicillin (100U/ml), and streptomycin (100U/ml) at 37°C and 
5% CO2, and checked routinely for mycoplasma and authenticated.  
 
Generation of Repeat Expansion Constructs 
Sense (TCGAC (G4C2)10) and antisense (ACGT(G4C2)10) oligonucleotides (Sigma-Aldrich) 
with SalI/XhoI overhangs were annealed by denaturing at 95ºC for 5 min and cooling at 
0.5ºC/min to 25ºC. The dsDNA (G4C2)10 was ligated into SalI and XhoI digested pcDNA6.2-
GW/EmGFP-miR (Invitrogen) to generate pcDNA6.2-GW-(G4C2)10. Further (G4C2)n repeats 
where n varied between 10-17 repeats were subcloned into the XhoI site to generate the longer 
pcDNA6.2-(G4C2)102 construct. The (G4C2)10 and (G4C2)102 constructs were subsequently sub-
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cloned into a pAV2-CMV (cytomegalovirus) plasmid and authenticity was confirmed by 
sequencing. Transformations of plasmids containing the (G4C2)n repeat constructs were 
performed using recombination-deficient β-10 E.coli (NEB) to minimise any rearrangements.  
 
Large scale scAAV9 production 
Sixty 15 cm plates containing HEK293 cells at 80% confluence were transfected using 
polyethylenimine (MW ~ 25K) with a mixture of three plasmids required to generate an 
infectious scAAV9 viral particle: (1) A plasmid providing helper genes isolated from 
adenovirus that enhance viral infectivity (pHelper); (2) An ITR-containing plasmid carrying 
the gene of interest (pAV2-CMV-(G4C2)n; we used the pAV2-CMV-GFP consisting of two 
ITRs in a truncated genome that resulted in a self-complementary AAV9 (scAAV9), as 
described by others (McCarty et al., 2001)); (3) A plasmid that carries the AAV Rep-Cap 
proteins (pAAV2/9). Each 15cm plate was transfected with a total of 40µg of DNA comprised 
of a 2:1:1 molar ratio of pHelper: pAV2-CMV-(G4C2)n: pAAV2/9. Four days after transfection, 
the AAV enriched media was collected, incubated at 37°C for 2 hours with 3,750 units of 
benzonase-nuclease (Sigma, USA), filtered through a 0.22 µm filter, and concentrated to a 
volume of 1ml using Amicon spin filter units (Millipore, USA). The virus was then washed 
with 50 ml of phosphate buffered saline (PBS, pH 7.3) in the same Amicon spin filter units, 
and concentrated to a final volume of 0.5 ml. The viral sample volume was expanded to 14ml 
with PBS and separated through a discontinuous iodixanol (D1556, Sigma, USA) gradient (4ml 
of 54%, 9 ml of 40%, 9 ml of 25%, 5 ml of 15%), and centrifuged at 69,000 rpm for 1.5 hours 
at 18°C. Phenol red was added to the 54% and 25% iodixanol layers to help with identifying 
the virus enriched layer. The purified virus was found as a white layer between the 54% and 
40% iodixanol gradient and subsequently removed in 0.5ml fractions using a syringe, with 10µl 
of each fraction mixed at an equal ratio with 2X reducing sample SDS-PAGE buffer, heated to 
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75°C for 20 minutes, separated on a 4-20% precast TGX mini-gel (Biorad, USA), and stained 
with Sypro-Ruby according to the manufacturer’s protocol (Life Techologies, USA). Fractions 
that showed a pure virus composed solely of the VP1, VP2 and VP3 bands were combined, 
and washed against 5 full volumes (15ml each) of PBS with an Amicon spin filter, before 
collecting in a final volume of between 300-500µl.  
 
Quantitative PCR to measure viral titres 
Viral titres were determined with the Quantifast SyBR Green PCR Kit (Qiagen, Cat 204054) 
on a BioRad CFX96 thermal cycler, following the manufacturer's instructions. The number of 
copies in three dilutions of a purified AAV9 virus (1/100, 1/1000, 1/10,000) were compared to 
a standard curve generated by serial dilutions of a linearized pAV2-CMV-(G4C2)n vector. 
Primers used to quantify viral genomes were (Poly A, Forward: 5’-ATT TTA TGT TTC AGG 
TTC AGG GGG AGG TG-3’), (PolyA, Reverse: 5’-GCG CAG AGA GGG AGT GGA CTA 
GT-3’).  
 
RNA Fluorescent in-situ hybridization (FISH) 
RNA FISH was performed as described previously (Cooper-Knock et al., 2014) with a few 
modifications. Briefly, a 5’ TYE-563-labelled LNA (16-mer fluorescent)-incorporated DNA 
probe was used against the sense RNA hexanucleotide repeat (Exiqon, Inc., batch number 
607323). Coronal brain sections (20 µm) directly cut onto slides were air dried, and then 
incubated in ice cold acetone for 10 minutes before washing in PBS. Slides were blocked with 
a hybridization solution [50% formamide, 2× saline sodium citrate (SSC), 100 mg/ml dextran 
sulphate, 50 mM sodium phosphate pH 7.0] for 1 h at 66°C and then incubated with 400 ng/ml 
of denatured probe in hybridization solution overnight at 66°C. After hybridization, slides were 
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washed once in 2×SSC/0.1% Tween-20 at room temperature and three times in 0.1× SSC at 
65°C and counterstained with Hoechst 33342. All solutions were made with DEPC-treated 
water. 
 
Generation of AAV9-mediated mouse model 
Mice were kept in a 12-hour dark/12-hour light cycle, with free access to food and water and a 
standardized room temperature, based on the UK Home Office Code of practice for the housing 
and care of animals used in scientific Act 1986. All in vivo experiments carried out in this study 
were performed according to the Animal (Scientific Procedures) Act 1986, under the Project 
License 40/3739, and were approved by the University of Sheffield Ethical Review Sub-
Committee and the UK Animal Procedures Committee (London, UK). 
 
Viruses (4.5x1010 vg; scAAV9-CMV-(G4C2)10 or scAAV9-CMV- (G4C2)102) were injected into 
the cerebrospinal fluid (CSF) of postnatal 1 (P1) male and female C57BL/6J wild-type mice, 
via the cisterna magna, under general anaesthesia. Pups from the same breeding pair were 
allocated randomly to the experimental groups. Viral delivery was carried out following the 
protocol described in previously (Lukashchuk et al., 2016). Briefly, pups were anaesthetized 
in an induction chamber using 5% isoflurane and oxygen at 3 L/min before placing the animal 
over a red transilluminator in the prone position. Viruses were loaded in a Hamilton syringe 
attached to a peristaltic pump and injected into the cisterna magna, using a stereotaxic 
apparatus, at a flow rate of 1 µl/min to a maximum volume of 5 µl. Anaesthesia was maintained 
with 2% isoflurane and oxygen at 0.3 L/min during the injection.  
 
Immunohistochemistry 
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Twelve months after injection, animals were sacrificed under terminal anaesthesia and 
transcardially perfused using a solution of PBS-heparin followed by 4% paraformaldehyde 
(PFA) in PBS. Brain and spinal cords were harvested and further post-fixed overnight in 4% 
PFA. After fixation, tissue was washed with PBS, cryoprotected in 30% of sucrose at 4°C, 
embedded in OCT (Cell Path®), and snap frozen in liquid nitrogen. Brains and spinal cords 
were cut in 20 μm thick coronal sections on a cryostat (Leica), placed directly onto silane 
treated slides, and then air dried. Sections were incubated with gentle agitation for 2 hours at 
room temperature in blocking buffer (PBS with 5% normal goat serum, 3% BSA and 0.2% 
Triton-X-100) before incubating overnight at 4°C with the appropriate antibody diluted in PBS 
with 3% BSA. Following three washes with PBS, sections were incubated with an appropriate 
alexa fluorophore conjugated secondary antibody (1:1000; Invitrogen, CA) for 1 hour at room 
temperature, counterstained with Hoechst 33342 and mounted onto slides with Fluoromount 
(Sigma). For visualizing DPR pathology, slides were immersed in   
sodium citrate buffer (10mM Sodium Citrate, 0.05% Tween 20, pH 6.0) for 30 minutes at 60°C 
before the blocking step. 
 
Neuromuscular junction (NMJ) pathology 
NMJ pathology was assessed on whole-mount immunohistochemically-labelled preparations 
of hindpaw lumbrical muscles from 1 year old mice, as described previously (Powis et al., 
2016, Wishart et al., 2014). Images were captured using a Nikon A1R confocal system 
combined with a Ti:E inverted microscope (×60 objective). Individual NMJs were assessed 
and abnormalities quantified, by eye, for evidence of neuromuscular pathology (presence of 
axonal blebbing/thinning or abnormal neurofilament accumulations in distal motor axons 
and/or motor nerve terminals). NMJ analysis was performed by investigators blinded to the 
treatment group.  
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Quantitative Fluorescence Imaging 
To assess the effect of CG repeats on the postsynaptic receptor density (marker of synapses), 
muscle cells were labeled with a saturating dose of fluorescent BTX (5 ug/ml, ~1 hour) and 
images of NMJs were collected using IPLAB software as described previously (Akaaboune et 
al., 1999, Martinez-Pena et al., 2015). The fluorescence intensity of labeled AChR was 
analyzed with algorithms for Matlab (The Mathworks).  Background fluorescence was 
determined by manual selection of a boundary region around the each NMJ and subtracting it 
from the original image, and the mean of the total fluorescence intensity (which corresponds 
to total fluorescence of that synapse divided by the area of that given synapse) was measured 
(Turney et al., 1996, Akaaboune et al., 1999, Martinez-Pena et al., 2015). All calculations of 
fluorescent intensities were made by investigators blinded to the mouse genotypes. 
 
Immunoblotting 
Adult mice were sacrificed using an overdose of sodium pentobarbitol, and brains were rapidly 
dissected and snap frozen with liquid nitrogen. Brains were then homogenised in RIPA buffer 
using a glass dounce homogenizer (150mM NaCl, 50mM Tris  pH8, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulphate (SDS), 1% NP-40 supplemented with 1X EDTA-
free protease inhibitor cocktail (Roche)) for 30 minutes on ice and centrifuged at 17,000 g at 
4°C for 10 minutes. Supernatant was then collected as a cytoplasmic fraction and used to 
examine p62 reactivity. To examine poly (GA) DPRs, the membrane enriched pellet was 
further solubilized in a buffer containing 1% Triton-X-100 and 0.5M NaCl in 10mM Tris-HCl 
(pH 7.4) for 45 minutes at 4°C with constant agitation and centrifuged at 17,000g at 4°C for 10 
minutes. Supernatant was collected as the triton-soluble fraction and the pellet was re-
suspended in a buffer containing 2% SDS in 10mM Tris-HCl (pH 7.4) and stored as the Triton 
insoluble fraction. Protein lysates were mixed with a 4X Laemmli buffer with 5% β-
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mercaptoethanol, heated to 95°C for 5 minutes, separated with a 10% SDS-PAGE and 
transferred onto a PVDF membrane (Millipore). Membranes were blocked with either 5% BSA 
or 5% nonfat dry milk in TBS with 0.05% Tween (TBST) for 30 minutes, before incubating at 
4°C overnight with agitation with the appropriate antibody diluted in 5% BSA in TBST. 
Following three washes in TBST for 10 minutes each, membranes were incubated at room 
temperature with mild agitation with an appropriate secondary HRP antibody (Sigma Aldrich, 
1:5000) diluted in 5% BSA in TBST, washed three times with TBST for 10 minutes each, and 
developed with enhanced chemiluminescent substrate (Amersham-Pharmacia Biotech, USA).      
 
Mouse Behavioural Tests 
All mouse behavioural experiments were performed with the experimenter blind to the mouse 
cohort groups. 
 
Open Field 
The open field was a 60cm x 40cm x 25cm semi-transparent plastic box with a grid of 3x5 
squares drawn on the underside of the box with black paint. Open field activity was measured 
in a room with minimal light for 10 minutes with the number of squares crossed recorded. A 
square crossing was defined as the passage of all four mouse paws over one of the boundaries 
of a square.  
 
Object Recognition 
Mice were tested for their ability to remember novel objects using a paradigm described by 
others (Leger et al., 2013). Briefly, on day 1 mice were habituated in a rectangular 60cm x 
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40cm x 25cm open field for three minutes. On the second day, mice were placed in the same 
box with two identical objects, and allowed to explore until a total of 20 seconds of exploration 
between the two objects had elapsed. Exploration was defined as mice actually sniffing, biting, 
touching with paws or examining the object. On the third day, one of the objects was replaced 
with a novel object, and the time measured at each object was recorded until a total of 20 
seconds had elapsed. To make sure that the objects were interesting enough to entice mice to 
explore them, the first object was a standard red capped 75cm2 tissue culture flask (Sigma, 
C7231) filled with a layer of purple dye treated agarose, while the second object was a stack 
of red slide boxes taped together.    
 
Gait analysis 
To analyse the gait pattern, 6 and 12 month old mice were placed on the Catwalk XT (Noldus®, 
Netherlands), where they had to traverse a narrow chamber in the dark. Their footprints were 
automatically recorded with the Catwalk 7.1 software from Noldus®. Six runs were performed 
per animal and the three best (chosen for mice walking along the chamber path as opposed to 
repeatedly stopping) were selected for analysis. All results are expressed as the average of 3 
runs ± SEM. The following parameters were measured and defined as: 
 Stand. The time the paws spends in contact with the Catwalk surface. 
 Base of support (BOS). Distance between either the front or hind paws. 
Diagonal support. Time spent on the Catwalk surface by a front paw and its opposing       
hind paw simultaneously (Right front paw – rear hind paw). 
Three support. Time spent on the Catwalk surface by three paws at the same time to 
support animal.  
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Swing. Time between two consecutive placements in which the paw is not in contact 
with the Catwalk surface. 
Swing speed. This parameter is calculated by dividing the stride length by the swing 
phase duration.  
 
Hind limb splay 
Twelve month old mice were suspended by the tail and the splay defects were observed and 
scored for right and left hind-limbs by using the following scale: 0:normal splay; 1:mild defect; 
2: moderate defect; 3: strong defect; 4: paralysed as previously described (Mead et al., 2011) 
The results show the average of each group ± SEM. 
Rotarod  
Performance on the rotarod (Ugo Basile 7650) was assessed every 2 weeks, twice per day, 
beginning 2 months after injection. Mice were initially trained for 3 consecutive days before 
the first trial. The rotarod was set to accelerate from 3 to 37 rpm in 300 seconds and the 
maximum time spent on the rotarod in a single trial out of two trials tested was recorded.  
 
Statistical Analysis 
Results are shown as mean ± standard error (S.E.M.). Student's unpaired t-test with a Welch’s 
correction for two group comparisons was used to assess differences between HRE-10 and 
HRE-102 mice. For comparisons between three groups (PBS injected, HRE-10 and HRE-102 
mice), a one-way analysis of variance (ANOVA) was used with Tukey's multiple comparison 
post-hoc test when p < 0.05. For assessing the effects of age on the gait and activity in each 
mouse cohort, we used a two-way ANOVA with a Sidak’s test for multiple comparisons when 
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p<0.05. No animals were excluded from any of the statistical analysis, and the cohorts were a 
mixture of male and female mice. For behavioural analysis, investigators were blinded to the 
mice being tested. All cell counts and RNA foci analysis were made by investigators blinded 
to the mouse genotypes. For all tests, a P-value < 0.05 was taken as statistically significant, 
and Graphpad Prism 6 was used for all statistical analyses. 
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Results 
 
Injection of AAV9-(G4C2)10 and AAV9-(G4C2)102 generate intranuclear RNA foci in vivo 
In these studies, we used self-complementary AAV9, due to its enhanced CNS transduction 
efficiency compared to single stranded AAV9 (McCarty et al., 2001) and its ability to achieve 
transduction in multiple regions of the mouse brain (Lukashchuk et al., 2016).  To generate 
mice expressing HREs, we first constructed two separate AAV9 vectors containing either 10 
or 102 HREs (Figure 1A). The AAV9-(G4C2)102 (referred to as HRE-102) construct was made 
by ligating between 10-17 HREs separated by a short TCGAG linker sequence, which results 
in mixed dipeptide repeat proteins. The advantages to using this approach are: firstly, the 
interruptions stabilized the sequence, reducing the risk of DNA rearrangements between the 
flanking inverted terminal repeats (ITRs) of the AAV; secondly, our HRE-102 did not have 
internal stop codons, which allowed us to test whether c9-pathological hallmarks, such as DPRs 
and TDP-43 aggregation, still persist in the presence of interrupted repeat sequences.  
 
Mice expressing repeat expansions were generated by delivering AAV9-HREs to early 
postnatal (P1) mice via the cisterna magna, which resulted in widespread transduction of the 
adult mouse brain as described in our previous work (Lukashchuk et al., 2016). Twelve months 
after AAV9 delivery, mice were sacrificed and different brain and spinal cord tissue was 
analysed using RNA fluorescent in situ hybridization (FISH) to see whether intracellular RNA 
foci were present. We found that the regions with the highest number of RNA foci per area are 
the brain stem, Purkinje cell layer of the cerebellum, CA1 and hilus of the hippocampus, 
midbrain, and cortex (Figure 1B-D). RNA foci were also detected in the spinal cord, even 
though they were less numerous in this region (Figure 1E). Surprisingly, there were no 
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significant differences in the number of RNA foci between the HRE-10 mice and HRE-102 in 
any of the regions examined (Figure 1F), suggesting that the formation of RNA foci is 
independent of the length of the G4C2 expansion. 
 
HRE-102 mice exhibit extensive DPR pathology, enhanced p62 expression, and dispersed 
CA1 neurons 
To test whether the AAV9-engineered mouse model develop other pathological hallmarks of 
ALS/FTD such as c9RAN protein aggregates, TDP-43 inclusions, and neuronal loss, we used 
a poly-GA antibody (Mackenzie et al., 2013) to probe for glycine-alanine rich DPRs in mouse 
brains. As shown in Figure 2, we detected either a homogenous nuclear expression (arrow) or 
an intense, discrete staining (arrowhead) within and outside of the nucleus (Figure 2A). These 
type of poly-GA pathology (diffuse or aggregate staining) which were most widely distributed 
in the cerebellum and brain stem, were visible only in HRE-102 (67%, n=6) treated mice, and 
absent in HRE-10 expressing (0%, n=6) mice. Analysis of triton-insoluble and soluble 
cerebellar/brain stem lysates isolated from a different group of HRE-10 and HRE-102 mice 
identified several different sized poly-GA peptides ranging from 25-63 kilodaltons in both 
triton-soluble and insoluble fractions solely in a subset of HRE-102 mice (Figure 2A-B). 
Additionally, the expression of p62, a marker of c9RAN pathology (Mori et al., 2013a, Mori 
et al., 2013b, Schludi et al., 2015), was enhanced in HRE-102 mice (Figure 2C). 
Next, we examined the expression of cleaved-caspase 3 and cleaved poly (ADP-ribose) 
polymerase (PARP) to see whether there was evidence of cells undergoing apoptosis. We 
focused our analysis on the cerebellum, due to the heightened DPR and p62 expression we 
observed in the HRE-102 mice (Figure 2A-C) that have been correlated to cell toxicity (Lee et 
al., 2016, Lopez-Gonzalez et al., 2016, Tran et al., 2015). As shown in Figures 2D-F, we found 
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that cleaved PARP in cerebellar purkinje cells and cleaved caspase-3 expression in the 
cerebellum were significantly increased in HRE-102 mice, indicating that that these areas were 
in the early stages of cell death. Interestingly, despite the presence of RNA foci and c9RAN 
pathology, neither astrogliosis (Figure S1) nor neurodegeneration in the cerebellum (Figure 
S2C-D) were observed. This absence of repeat-length dependent neurodegeneration was also 
observed in other such as the cortex (Figure S2A-B), spinal cord (Figure S2E-F) and 
hippocampus (Figure 2D-E), though there was a significant dispersal in the CA1 (Figure 2G-
H) that is characteristic of reeler mutant mice (Howell et al., 1997, Trommsdorff et al., 1999). 
Additionally, although we were able to detect infrequent TDP-43 clusters (Figure S3A-B) in 
the cerebellum, cortex, midbrain and hippocampus of HRE-10 and HRE-102, there was no 
significant difference between mouse groups with respect to TDP-43 pathology. In contrast to 
the largely nuclear TDP-43 pathology reported by Chew et al (2015), the majority of TDP-43 
aggregates in both groups of AAV-HRE injected mice were either at the perinuclear region or 
in the cytoplasm (Figure S3C).  
    
HRE-102 mice develop disease-related neuromuscular junction (NMJ) pathology 
In the absence of significant loss of neuronal cell bodies in the CNS in both mouse cohorts and  
since NMJ pathology is present in several different mouse models of ALS (Iguchi et al., 2013, 
Frey et al., 2000, Murray et al., 2010, Bennett et al., 2014), we asked whether peripheral 
neuromuscular junctions were altered in the HRE-102 expressing mice. To do this, muscles 
from twelve-month old mice were doubly labelled with an anti-neurofilament antibody to label 
nerve terminals and fluorescent bungarotoxin to label acetylcholine receptors (AChRs), and 
NMJs were imaged with a confocal microscope. A close inspection of NMJs revealed a 
significant increase in pathological NMJs in HRE-102 mice, defined as having abnormal pre-
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synaptic neurofilament accumulations and/or nerve terminal blebbings (Figure 3A,B), 
indicating that the NMJ may be an early target of c9-related toxicity. It well established that 
the density of postsynaptic AChR is significantly reduced in mouse models of motor neurons 
disease and myasthenia gravis (Losen et al., 2005, Kong et al., 2009). Here we asked whether 
the density of AChR at NMJs of HRE-102 mice is also altered. AChRs were labeled with BTX-
594 and the density of AChR at NMJs of HRE-102, HRE-10 and PBS were compared (Figure 
3C-D). The total fluorescence of AChRs (which measured fluorescence of a synapse per area 
of the synapse) was decreased by 20% in muscles expressing HRE-102 compared with NMJs 
of PBS injected mice. These results indicate that HRE-102 expression reduces the density of 
AChRs at postsynaptic sites. Collectively, HRE-102 mice exhibit a loss in NMJ integrity at 12 
months of age that is consistent with the early stages of motor neuron degeneration.  
   
HRE-102 mice have progressive gait and behavioural deficits 
To assess whether the c9RAN and NMJ pathology have any consequences on mouse 
behaviour, we analysed motor and cognitive tasks. We used a Catwalk system to examine 
different parameters measuring motor coordination and gait in ambulatory mice, and found that 
HRE-102 mice had gait abnormalities, with significantly irregular gait patterns compared to 
HRE-10 mice in the stand, base of support (BOS), diagonal support and three support 
parameters (Figure 4A). When we assessed the hindlimb splay in the two cohorts (HRE-10 and 
HRE-102), we found that there was a significant defect in the right hindlimb in the HRE-102 
mice (Figure 4B). These deficits did not appear to affect the exploratory activity of the mice as 
HRE-102 mice were not significantly different to HRE-10 mice in the open field at 12 months 
of age (Figure 4C). When we analyzed data between 6 and 12 months of age from several of 
the same tasks, we noted that most of the gait parameters including ones for measuring stride 
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irregularities (stand, swing, and swing speed) in addition to activity in the open field showed 
significant deterioration with age in the HRE-102 mice (Figure S4A-D), demonstrating that the 
behavioural impairments in HRE-102 mice were progressive. There were, however, no 
differences between groups in the accelerating rotarod over the ten months of testing (Figure 
S4E). We next used the object recognition paradigm to determine whether the HRE-102 mice 
had any cognitive deficits which could correlate with the CA1 dispersal demonstrated in Figure 
2D. This behavioural task exploits the innate interest of mice to explore a novel object by 
forcing mice to discriminate between a novel object and an object previously explored. Both 
sets of mice explored two novel objects without any significant difference in the familiarization 
phase (Figure 4D), but only HRE-102 mice were unable to discriminate between a novel object 
and one they had previously explored, indicating the presence of a memory deficit.  
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Discussion 
Current mouse models of C9orf72 ALS/FTD have supported a toxic gain of function 
mechanism by which long G4C2 hexanucleotide RNA expansions (HREs) induce the formation 
of intracellular RNA foci and RAN protein aggregates leading to toxicity and behavioural 
dysfunction. One of several issues which remains unclear, however, is the minimum pathogenic 
size of the repeats and specific mixture of factors necessary for generating disease. Here we 
have directly addressed this important question by developing a new model of C9orf72 
ALS/FTD utilizing AAV9 to express either 10 or 102 interrupted G4C2 repeat expansions, and 
demonstrate that while both lines of mice have similar numbers of RNA foci dispersed through 
the brain, only AAV-HRE-102 mice generate c9RAN pathology, exhibit NMJ pathology, 
hippocampal CA1 dispersion, early markers of apoptosis, and display gait and cognitive 
deficits.   
 
To date, four independent mouse models expressing either a full length or truncated human 
C9orf72 have been generated with hundreds of HREs along with an AAV-mediated model 
expressing a shorter (66) number of HREs. All of these mouse models have detectable RNA 
foci and c9RAN aggregates in the brain, though the minimum size necessary to induce RNA 
foci formation differs widely. Expression of a full length C9orf72 bacterial artificial 
chromosome (BAC) transgene in mice was unable to induce RNA foci formation with even 
36-37  HREs (Liu et al., 2016, O'Rourke et al., 2015), and in mice expressing truncated 
C9orf72, expression of even 100 G4C2 expansions yield limited RNA foci (Jiang et al., 2016). 
In contrast, AAV mediated expression of 66 HREs resulted in mice displaying significant 
ALS/FTD pathology (Chew et al., 2015). The likely major difference between model systems 
is that AAV based models can utilize a strong promoter to drive expression such as the actin 
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promoter used by Chew et al. (2015) or the cytomegalovirus (CMV) promoter we have used in 
the present study. In the AAV C9orf72 model described by Chew et al. (2015), expression of 
only two HREs failed to generate any RNA foci or DPRs. We chose a higher minimum 
expansion length of 10 HREs to get a better gauge of whether the expression of RNA foci and 
RAN translated DPRs were linked, since we had detected RNA foci in both cell lines and 
primary neurons transduced with HRE-10 (unpublished observations). Surprisingly, our mouse 
models expressing HRE-10 and HRE-102 yield similar numbers of RNA foci in the CNS 
(Figure 1F), and we therefore conclude that RNA foci density is not dependent on the length 
of an expansion repeat once a minimum threshold has been crossed.    
 
Although other groups have shown that crossing a minimum HRE threshold may be necessary 
to induce DPR formation (Mizielinska et al., 2014, Zu et al., 2011), there is a report of BAC 
C9 transgenic mice overexpressing 36/37 HREs and forming poly-GA aggregates without 
RNA foci formation (Liu et al., 2016). There remains the possibility, therefore, that RNA foci 
and DPRs arise independently of each other. Our data support a relationship between expansion 
repeat length and DPR formation since only the HRE-102 mice expressed DPRs (Figure 2A-
B) as well as increased p62 staining (Figure 2C), which frequently co-localizes with poly-GA 
DPRs (Schludi et al., 2015). The presence of DPRs in our HRE-102 mice also indicates that 
the interruptions we introduced between every 10-17 GGGGCC repeats do not prevent protein 
expression, unlike the interrupted HREs expressed in Drosophila melanogaster (Mizielinska 
et al., 2014).  This is probably due to the absence of stop codons within the repeat expansions 
in our AAV construct, demonstrating that a pure (G4C2)n sequence is not necessarily required 
to induce RAN translation and the formation of either diffuse protein expression or aggregates.  
There is a growing consensus that DPR expression is toxic to cells, and a key factor in C9-
related disease (Zhang et al., 2015, Lee et al., 2016, Mizielinska et al., 2014), although two of 
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the BAC transgenic C9-mouse models generate DPRs without any concomitant 
neurodegeneration or behavioral dysfunction (Peters et al., 2015, O'Rourke et al., 2015). Our 
data support a link between DPRs and toxicity; HRE-102 mice express DPRs and have 
progressive gait, activity and cognitive deficits along with changes in the integrity of the NMJ 
that are absent in HRE-10 mice. Additionally, the HRE-102 mice show early signs of apoptosis 
including an increased expression of cleaved caspase-3 (Figure 2F) and cleaved PARP 
expression (Figure 2G-H) in the cerebellum, which had the highest concentration of DPRs. In 
contrast to the largely nuclear DPRs generated in mice expressing HRE-66 with AAV9 (Chew 
et al., 2015), our AAV9 mediated HRE-102 mice primarily showed discrete DPR aggregates 
in the cytoplasm (Figure 2A), similar to several human C9orf72 BAC transgenic models (Jiang 
et al., 2016, O'Rourke et al., 2015, Peters et al., 2015) and observed in C9ALS/FTD patients 
(Mori et al., 2013a, Mori et al., 2013b, Schludi et al., 2015).  Our data therefore supports a 
repeat-length dependent change in the formation of DPRs and suggest that even with a strong 
constitutive promoter, there needs to be more than 66 HREs to detect DPRs in the cytoplasm.    
 
As HREs in C9orf72 are a major cause of FTD, and progressive deficits in spatial learning and 
memory and have been reported in C9orf72 BAC transgenic mice expressing 450 repeats 
linked to mild neuronal loss in the dentate gyrus and hippocampal CA1 (Jiang et al., 2016), we 
carefully examined hippocampal pathology in the AAV-mediated mouse models since the 
HRE-102 mice failed to discriminate between familiar and novel objects, demonstrating the 
presence of a cognitive deficit (Figure 4D). Previously, DPRs in the hippocampal CA1 of 
patients with C9-repeats have been reported (Pletnikova et al., 2014), but while we did not 
detect DPRs in the hippocampus, we did observe a dispersal of the CA1 (Figure 2D-E) in the 
HRE-102 mice that was reminiscent of the aberrant neuronal migration phenotype of 
Reeler/Disabled-1 mouse mutants that occurs during early development (Trommsdorff et al., 
24 
 
1999, Howell et al., 1997). Interestingly knockdown of Reelin, the glycoprotein absent in 
Reeler mutant mice, impairs rats in the object recognition task, while Reelin overexpression 
can rescue deficits in the object recognition task in mouse models of Alzheimer's disease 
(Brosda et al., 2011, Pujadas et al., 2014). Further analysis will be necessary to determine 
whether any link between Reelin and C9orf72 exists.    
 
In summary, these data support a repeat-expansion length dependent gain of toxicity, with 
c9RAN formation being the likely driver of pathogenesis as the gait, motor and cognitive 
deficits precede any major TDP-43 pathology. Our mouse models, generated through AAV-
mediated expression of HREs, have allowed us to uncouple the relationship between RNA foci 
pathology, DPR formation and repeat expansion length. RNA foci pathology is not dependent 
on the length of the repeat expansion, and appears to be independent of both DPR formation as 
well as disease relevant behavioral phenotypes in our AAV-HRE expressing mice. In our 
mouse model expressing 102 HREs, the structural changes in the NMJ may correspond to the 
observed gait abnormalities, and changes in CA1 integrity may be linked to cognitive deficits, 
though further evaluation in the future will be necessary to assess this. Our studies establish a 
new mouse model generated by utilizing AAV9 to achieve widespread expression of HREs in 
mice, which will be useful for identifying therapeutic strategies that ameliorate DPR toxicity.   
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Figure Legends 
Figure 1. AAV9-HREs can generate RNA foci in the mouse CNS. (A) Two different HREs 
were designed and subcloned into AAV9 vectors with the (G4C2)102 expansions constructed by 
a mixture of (G4C2)10-17 oligonucleotides with an intervening linker sequence. (B-F) RNA 
fluorescent in situ hybridization was used to detect RNA foci, which were abundant in the (B) 
hippocampus (HC), (C) cortex (CTX), (D) cerebellum (CB) and sparse in the (E) spinal cord 
(SC, *motor neuron). (F) There were no significant differences in the number of foci detected 
per mm2 in either the HC (n=3 for each, p=0.28), CTX (n=3 for each, p=0.43), or CB (n=6 for 
each, p=0.73) between HRE-10 and HRE-102 mice as assessed using an unpaired two-tailed 
Student’s t-test with Welch’s correction for each region. Scale bar is 10µm. Nuclei stained 
blue. 
Figure 2. Dipeptide protein repeat (DPR) pathology, hippocampal CA1 dispersal, and 
upregulation of cell death markers are observed in HRE-102 mice. (A) Cytoplasmic and 
nuclear DPRs adopt several morphologies in a subset of HRE-102 mice using a poly-(GA) 
antibody in cerebellar tissue. (B) Immunoblots of cerebellar lysates show that both triton 
soluble and triton insoluble proteins contain GA-rich DPRs in HRE-102 mice, and were never 
observed in HRE-10 mice. (C) HRE-102 mice show an increased p62 expression compared to 
HRE-10 mice in cerebellar tissue; arrowhead shows 60 kD isoform that was consistently absent 
in HRE-10 brains. (D-E) A significant number of Purkinje cells in the cerebellum of HRE-102 
mice show signs of early apoptosis reflected by cleaved PARP immunoreactivity (n=4 for both, 
p=0.046). (F) Enhanced cleaved-caspase-3 expression is observed in cerebellar lysates from 
HRE-102 mice. (G-H) There were no differences in the number of neurons as determined by 
NeuN staining in the dentate gyrus (DG, HRE-10 (n=4), HRE-100 (n=6); p=0.66) or CA3 
(HRE-10 (n=4), HRE-100 (n=6); p=0.69) in the hippocampus between HRE-10 and HRE-102, 
but there was a significant dispersal of CA1 neurons in HRE-102 mice (HRE-10 (n=4), HRE-
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100 (n=6); p=0.046). Nuclei stained blue. All comparisons were made with an unpaired two-
tailed Student's t-test with Welch’s correction; mean ± SEM. Scale bar: (A): 10 µm, (D): 25 
µm, (G): 10 µm 
Figure 3. Neuromuscular junction (NMJ) defects are present in the HRE-102 mice. (A-B) 
Abnormal neurofilament accumulation and nerve terminal blebbings (arrows) were prominent 
in HRE-102 mice (PBS:n=3, HRE-10:n=4, HRE-102:n=4; n=individual muscles per genotype; 
(F(2,8)=6.47, *p=0.02, post-hoc Tukey: HRE-10 vs PBS (p=0.19); HRE-10 vs HRE-102 
(p=0.23); HRE-102 vs PBS (p=0.02)); scale bar 30 µm. (C-D) HRE-102 mice have a significant 
decrease in acetylcholine receptor density compared to PBS injected controls (F(2,7)=10.79, 
**p=0.007, post-hoc Tukey: HRE-10 vs PBS (p=0.16); HRE-10 vs HRE-102 (p=0.056); HRE-
102 vs PBS (p=0.006)).  The fluorescence intensity (total fluorescence of that synapse divided 
by the area of that given synapse) of a saturating dose of α-bungarotoxin-alexa fluor 594 was 
measured and normalized to PBS controls. All comparisons were made with a one-way 
ANOVA and post-hoc Tukey for comparisons between groups; mean ± SEM. 
Figure 4. Gait and cognitive deficits observed in HRE-102 mice are absent in HRE-10 
mice in 12 month old mice. (A) Gait abnormalities such as the front and hind stand index, the 
hind base of support (BOS), the diagonal support and the three-legged support were observed 
using a Catwalk system in HRE-102 mice (HRE-10 (n=11), HRE-100 (n=13) for each; front 
stand:*p=0.04, hind stand:*p=0.04; front BOS:p=0.19, hind BOS:*p=0.02; diagonal 
support:*p=0.01, three-legged support:**p=0.006). (B)  HRE-102 mice (n=13) had a moderate 
splay in the right (*p=0.04) but not left (p=0.59) hindlimb compared to HRE-10 mice (n=11). 
(C) There were no significant differences in activity (p=0.15) between HRE-10 (n=11) and 
HRE-102 (n=13) in the open field. (D) An object recognition test identified a cognitive deficit 
in HRE-102 mice (n=13) as they failed to discriminate in the testing phase (HRE-
102:familiarization phase: p=0.43, testing phase: p=0.09) between a novel object and an object 
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previously explored in the familiarization phase unlike HRE-10 mice (n=11, familiarization 
phase:p=0.57, testing phase:*p=0.02). All comparisons were made with an unpaired two-tailed 
Student's t-test with Welch’s correction; mean ± SEM.  
       
Figure S1. No differences in astrogliosis between HRE-10 and HRE-102 mice. GFAP 
immunoreactivity in twelve-month cerebellar tissue was similar between HRE-10 and HRE-
102 mice (n=3 for each; p=0.79, unpaired two-tailed Student's t-test; mean ± SEM).   
Figure S2. No evidence of loss of neuronal cell bodies in the cortex or cerebellum of HRE-
102 mice. (A) NeuN immunoreactivity in the cortex in twelve-month cortical tissue was not 
significantly different (B) between repeat expansion mice (n=5 for each; p=0.15, unpaired two-
tailed Student's t-test with Welch’s correction; mean ± SEM).  (C) Calbindin immunoreactivity, 
used to label Purkinje cells in the cerebellum, was not significantly different (D) between HRE-
10 and HRE-102 mice (n=5 for each; p=0.37, unpaired two-tailed Student's t-test with Welch’s 
correction; mean ± SEM). (E) Nissl staining of spinal cord sections show that there are no 
significant differences (F) between HRE-10 and HRE-102 in the number of motor neurons in 
the spinal cord (n=3 for each; p=0.87, unpaired two-tailed Student's t-test with Welch’s 
correction; mean ± SEM). Scale bar for (A): 10µm, (C): 20µm, (E): 20 µm. 
Figure S3. No differences in presence of TDP-43 aggregates between HRE-10 and HRE-
102 mice. (A) Infrequent TDP-43 aggregates were identified in brain tissue in (B) multiple 
regions, though there were no significant differences detected between the HRE-10 and HRE-
102 mice in either the cerebellum (CB, n=3 for each; p=0.89), cortex (CTX, n=6 for each; 
p=0.48), hippocampus (HC, n=6 for each; p=0.93), or midbrain (MB, n=6 for each; p=0.15). 
(C) The majority of TDP-43 aggregates were found outside (O, HRE-10:n=6, HRE-102:n=5; 
p=0.87) the nucleus, with the perinuclear (P, HRE-10:n=6, HRE-102:n=5; p=0.60) and nuclear 
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(N, HRE-10:n=6, HRE-102:n=5; p=0.52) localization in the minority. An unpaired two-tailed 
Student's t-test was used to assess data between the two mouse groups for all comparisons. 
Scale bar for (A): 50µm, (C): 5µm. Nuclei stained blue.         
 
Fig S4. HRE-102 mice show age-related deficits in gait and activity compared to HRE-10 
mice. (A-C) Progressive changes in HRE-102 mice in several gait phenotypes such as the front 
and hind stand index, front and hind swing speed, and front and hind swing are not observed 
in HRE-10 mice (HRE-10:n=11, HRE-102:n=13; front stand index:[F(1,42)=17.87, 
***p=0.0001, post-hoc Sidek: HRE-10 (p=0.29), HRE-102 (p<0.0001)], hind stand 
index:[F(1,42)=18.63, ****p<0.0001, post-hoc Sidek:HRE-10 (p=0.17), HRE-102 
(p=0.0001)], front swing speed:[F(1,42)=10.93, **p=0.002, post-hoc Sidek:HRE-10 (p=0.22), 
HRE-102 (p=0.007)], hind swing speed:[F(1,42)=9.27, **p=0.004, post-hoc Sidek:HRE-10 
(p=0.49), HRE-102 (p=0.004)], front swing:[F(1,42)=15.96, ***p=0.0003, post-hoc 
Sidek:HRE-10 (p=0.15), HRE-102 (p=0.0007)], hind swing:[F(1,42)=14.46, ***p=0.0005, 
post-hoc Sidek:HRE-10 (p=0.42), HRE-102 (p=0.0002)]. (D) HRE-102 mice were 
increasingly hypoactive with age in the open field in contrast to HRE-10 mice (HRE-10:n=10, 
HRE-102:n=13; front stand index:[F(1,42)=9.69, **p=0.003, post-hoc Sidek: HRE-10 
(p=0.36), HRE-102 (p=0.005)]. (E) There were no differences on the accelerating rotarod 
between HRE-10 and HRE-102 mice [F(22,484)=0.84, p=0.67]; Two-way ANOVA, genotype 
x age interaction, all data presented as mean ± SEM. 
 
  
30 
 
 
 
 
References 
AKAABOUNE, M., CULICAN, S. M., TURNEY, S. G. & LICHTMAN, J. W. 1999. Rapid 
and reversible effects of activity on acetylcholine receptor density at the neuromuscular 
junction in vivo. Science, 286, 503-7. 
BELZIL, V. V., BAUER, P. O., PRUDENCIO, M., GENDRON, T. F., STETLER, C. T., 
YAN, I. K., PREGENT, L., DAUGHRITY, L., BAKER, M. C., RADEMAKERS, R., 
BOYLAN, K., PATEL, T. C., DICKSON, D. W. & PETRUCELLI, L. 2013. Reduced 
C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic 
event detectable in blood. Acta Neuropathol, 126, 895-905. 
BENNETT, E. J., MEAD, R. J., AZZOUZ, M., SHAW, P. J. & GRIERSON, A. J. 2014. 
Early detection of motor dysfunction in the SOD1G93A mouse model of Amyotrophic 
Lateral Sclerosis (ALS) using home cage running wheels. PLoS One, 9, e107918. 
BROSDA, J., DIETZ, F. & KOCH, M. 2011. Impairment of cognitive performance after 
reelin knockdown in the medial prefrontal cortex of pubertal or adult rats. Neurobiol Dis, 44, 
239-47. 
CHEW, J., GENDRON, T. F., PRUDENCIO, M., SASAGURI, H., ZHANG, Y. J., 
CASTANEDES-CASEY, M., LEE, C. W., JANSEN-WEST, K., KURTI, A., MURRAY, M. 
E., BIENIEK, K. F., BAUER, P. O., WHITELAW, E. C., ROUSSEAU, L., STANKOWSKI, 
J. N., STETLER, C., DAUGHRITY, L. M., PERKERSON, E. A., DESARO, P., 
JOHNSTON, A., OVERSTREET, K., EDBAUER, D., RADEMAKERS, R., BOYLAN, K. 
B., DICKSON, D. W., FRYER, J. D. & PETRUCELLI, L. 2015. Neurodegeneration. 
C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral 
deficits. Science, 348, 1151-4. 
COOPER-KNOCK, J., WALSH, M. J., HIGGINBOTTOM, A., ROBIN HIGHLEY, J., 
DICKMAN, M. J., EDBAUER, D., INCE, P. G., WHARTON, S. B., WILSON, S. A., 
KIRBY, J., HAUTBERGUE, G. M. & SHAW, P. J. 2014. Sequestration of multiple RNA 
recognition motif-containing proteins by C9orf72 repeat expansions. Brain, 137, 2040-51. 
DEJESUS-HERNANDEZ, M., MACKENZIE, I. R., BOEVE, B. F., BOXER, A. L., 
BAKER, M., RUTHERFORD, N. J., NICHOLSON, A. M., FINCH, N. A., FLYNN, H., 
ADAMSON, J., KOURI, N., WOJTAS, A., SENGDY, P., HSIUNG, G. Y., KARYDAS, A., 
SEELEY, W. W., JOSEPHS, K. A., COPPOLA, G., GESCHWIND, D. H., WSZOLEK, Z. 
K., FELDMAN, H., KNOPMAN, D. S., PETERSEN, R. C., MILLER, B. L., DICKSON, D. 
W., BOYLAN, K. B., GRAFF-RADFORD, N. R. & RADEMAKERS, R. 2011. Expanded 
31 
 
GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-
linked FTD and ALS. Neuron, 72, 245-56. 
DONNELLY, C. J., ZHANG, P. W., PHAM, J. T., HAEUSLER, A. R., MISTRY, N. A., 
VIDENSKY, S., DALEY, E. L., POTH, E. M., HOOVER, B., FINES, D. M., 
MARAGAKIS, N., TIENARI, P. J., PETRUCELLI, L., TRAYNOR, B. J., WANG, J., 
RIGO, F., BENNETT, C. F., BLACKSHAW, S., SATTLER, R. & ROTHSTEIN, J. D. 2013. 
RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. 
Neuron, 80, 415-28. 
FREIBAUM, B. D., LU, Y., LOPEZ-GONZALEZ, R., KIM, N. C., ALMEIDA, S., LEE, K. 
H., BADDERS, N., VALENTINE, M., MILLER, B. L., WONG, P. C., PETRUCELLI, L., 
KIM, H. J., GAO, F. B. & TAYLOR, J. P. 2015. GGGGCC repeat expansion in C9orf72 
compromises nucleocytoplasmic transport. Nature, 525, 129-33. 
FREY, D., SCHNEIDER, C., XU, L., BORG, J., SPOOREN, W. & CARONI, P. 2000. Early 
and selective loss of neuromuscular synapse subtypes with low sprouting competence in 
motoneuron diseases. J Neurosci, 20, 2534-42. 
HOWELL, B. W., HAWKES, R., SORIANO, P. & COOPER, J. A. 1997. Neuronal position 
in the developing brain is regulated by mouse disabled-1. Nature, 389, 733-7. 
IGUCHI, Y., KATSUNO, M., NIWA, J., TAKAGI, S., ISHIGAKI, S., IKENAKA, K., 
KAWAI, K., WATANABE, H., YAMANAKA, K., TAKAHASHI, R., MISAWA, H., 
SASAKI, S., TANAKA, F. & SOBUE, G. 2013. Loss of TDP-43 causes age-dependent 
progressive motor neuron degeneration. Brain, 136, 1371-82. 
JIANG, J., ZHU, Q., GENDRON, T. F., SABERI, S., MCALONIS-DOWNES, M., 
SEELMAN, A., STAUFFER, J. E., JAFAR-NEJAD, P., DRENNER, K., SCHULTE, D., 
CHUN, S., SUN, S., LING, S. C., MYERS, B., ENGELHARDT, J., KATZ, M., BAUGHN, 
M., PLATOSHYN, O., MARSALA, M., WATT, A., HEYSER, C. J., ARD, M. C., DE 
MUYNCK, L., DAUGHRITY, L. M., SWING, D. A., TESSAROLLO, L., JUNG, C. J., 
DELPOUX, A., UTZSCHNEIDER, D. T., HEDRICK, S. M., DE JONG, P. J., EDBAUER, 
D., VAN DAMME, P., PETRUCELLI, L., SHAW, C. E., BENNETT, C. F., DA CRUZ, S., 
RAVITS, J., RIGO, F., CLEVELAND, D. W. & LAGIER-TOURENNE, C. 2016. Gain of 
Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense 
Oligonucleotides Targeting GGGGCC-Containing RNAs. Neuron, 90, 535-50. 
KONG, L., WANG, X., CHOE, D. W., POLLEY, M., BURNETT, B. G., BOSCH-MARCÉ, 
M., GRIFFIN, J. W., RICH, M. M. & SUMNER, C. J. 2009. Impaired synaptic vesicle 
release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. J 
Neurosci, 29, 842-51. 
KOPPERS, M., BLOKHUIS, A. M., WESTENENG, H. J., TERPSTRA, M. L., ZUNDEL, C. 
A., VIEIRA DE SA, R., SCHELLEVIS, R. D., WAITE, A. J., BLAKE, D. J., VELDINK, J. 
H., VAN DEN BERG, L. H. & PASTERKAMP, R. J. 2015. C9orf72 ablation in mice does 
not cause motor neuron degeneration or motor deficits. Ann Neurol, 78, 426-38. 
32 
 
LEE, K. H., ZHANG, P., KIM, H. J., MITREA, D. M., SARKAR, M., FREIBAUM, B. D., 
CIKA, J., COUGHLIN, M., MESSING, J., MOLLIEX, A., MAXWELL, B. A., KIM, N. C., 
TEMIROV, J., MOORE, J., KOLAITIS, R. M., SHAW, T. I., BAI, B., PENG, J., 
KRIWACKI, R. W. & TAYLOR, J. P. 2016. C9orf72 Dipeptide Repeats Impair the 
Assembly, Dynamics, and Function of Membrane-Less Organelles. Cell, 167, 774-788 e17. 
LEGER, M., QUIEDEVILLE, A., BOUET, V., HAELEWYN, B., BOULOUARD, M., 
SCHUMANN-BARD, P. & FRERET, T. 2013. Object recognition test in mice. Nat Protoc, 
8, 2531-7. 
LIU, Y., PATTAMATTA, A., ZU, T., REID, T., BARDHI, O., BORCHELT, D. R., 
YACHNIS, A. T. & RANUM, L. P. 2016. C9orf72 BAC Mouse Model with Motor Deficits 
and Neurodegenerative Features of ALS/FTD. Neuron, 90, 521-34. 
LOPEZ-GONZALEZ, R., LU, Y., GENDRON, T. F., KARYDAS, A., TRAN, H., YANG, 
D., PETRUCELLI, L., MILLER, B. L., ALMEIDA, S. & GAO, F. B. 2016. Poly(GR) in 
C9ORF72-Related ALS/FTD Compromises Mitochondrial Function and Increases Oxidative 
Stress and DNA Damage in iPSC-Derived Motor Neurons. Neuron, 92, 383-391. 
LOSEN, M., STASSEN, M. H., MARTÍNEZ-MARTÍNEZ, P., MACHIELS, B. M., 
DUIMEL, H., FREDERIK, P., VELDMAN, H., WOKKE, J. H., SPAANS, F., VINCENT, 
A. & DE BAETS, M. H. 2005. Increased expression of rapsyn in muscles prevents 
acetylcholine receptor loss in experimental autoimmune myasthenia gravis. Brain, 128, 2327-
37. 
LUKASHCHUK, V., LEWIS, K. E., COLDICOTT, I., GRIERSON, A. J. & AZZOUZ, M. 
2016. AAV9-mediated central nervous system-targeted gene delivery via cisterna magna 
route in mice. Mol Ther Methods Clin Dev, 3, 15055. 
MACKENZIE, I. R., ARZBERGER, T., KREMMER, E., TROOST, D., LORENZL, S., 
MORI, K., WENG, S. M., HAASS, C., KRETZSCHMAR, H. A., EDBAUER, D. & 
NEUMANN, M. 2013. Dipeptide repeat protein pathology in C9ORF72 mutation cases: 
clinico-pathological correlations. Acta Neuropathol, 126, 859-79. 
MAJOUNIE, E., RENTON, A. E., MOK, K., DOPPER, E. G., WAITE, A., ROLLINSON, 
S., CHIO, A., RESTAGNO, G., NICOLAOU, N., SIMON-SANCHEZ, J., VAN SWIETEN, 
J. C., ABRAMZON, Y., JOHNSON, J. O., SENDTNER, M., PAMPHLETT, R., ORRELL, 
R. W., MEAD, S., SIDLE, K. C., HOULDEN, H., ROHRER, J. D., MORRISON, K. E., 
PALL, H., TALBOT, K., ANSORGE, O., CHROMOSOME, A. L. S. F. T. D. C., FRENCH 
RESEARCH NETWORK ON, F. F. A., CONSORTIUM, I., HERNANDEZ, D. G., 
AREPALLI, S., SABATELLI, M., MORA, G., CORBO, M., GIANNINI, F., CALVO, A., 
ENGLUND, E., BORGHERO, G., FLORIS, G. L., REMES, A. M., LAAKSOVIRTA, H., 
MCCLUSKEY, L., TROJANOWSKI, J. Q., VAN DEERLIN, V. M., SCHELLENBERG, G. 
D., NALLS, M. A., DRORY, V. E., LU, C. S., YEH, T. H., ISHIURA, H., TAKAHASHI, 
Y., TSUJI, S., LE BER, I., BRICE, A., DREPPER, C., WILLIAMS, N., KIRBY, J., SHAW, 
P., HARDY, J., TIENARI, P. J., HEUTINK, P., MORRIS, H. R., PICKERING-BROWN, S. 
& TRAYNOR, B. J. 2012. Frequency of the C9orf72 hexanucleotide repeat expansion in 
33 
 
patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional 
study. Lancet Neurol, 11, 323-30. 
MARTINEZ-PENA, Y. V. I., AITTALEB, M., CHEN, P. J. & AKAABOUNE, M. 2015. 
The knockdown of alphakap alters the postsynaptic apparatus of neuromuscular junctions in 
living mice. J Neurosci, 35, 5118-27. 
MCCARTY, D. M., MONAHAN, P. E. & SAMULSKI, R. J. 2001. Self-complementary 
recombinant adeno-associated virus (scAAV) vectors promote efficient transduction 
independently of DNA synthesis. Gene Ther, 8, 1248-54. 
MEAD, R. J., BENNETT, E. J., KENNERLEY, A. J., SHARP, P., SUNYACH, C., 
KASHER, P., BERWICK, J., PETTMANN, B., BATTAGLIA, G., AZZOUZ, M., 
GRIERSON, A. & SHAW, P. J. 2011. Optimised and rapid pre-clinical screening in the 
SOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS). PLoS One, 6, 
e23244. 
MIZIELINSKA, S., GRONKE, S., NICCOLI, T., RIDLER, C. E., CLAYTON, E. L., 
DEVOY, A., MOENS, T., NORONA, F. E., WOOLLACOTT, I. O., PIETRZYK, J., 
CLEVERLEY, K., NICOLL, A. J., PICKERING-BROWN, S., DOLS, J., CABECINHA, M., 
HENDRICH, O., FRATTA, P., FISHER, E. M., PARTRIDGE, L. & ISAACS, A. M. 2014. 
C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich 
proteins. Science, 345, 1192-4. 
MORI, K., ARZBERGER, T., GRASSER, F. A., GIJSELINCK, I., MAY, S., RENTZSCH, 
K., WENG, S. M., SCHLUDI, M. H., VAN DER ZEE, J., CRUTS, M., VAN 
BROECKHOVEN, C., KREMMER, E., KRETZSCHMAR, H. A., HAASS, C. & 
EDBAUER, D. 2013a. Bidirectional transcripts of the expanded C9orf72 hexanucleotide 
repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol, 126, 881-
93. 
MORI, K., WENG, S. M., ARZBERGER, T., MAY, S., RENTZSCH, K., KREMMER, E., 
SCHMID, B., KRETZSCHMAR, H. A., CRUTS, M., VAN BROECKHOVEN, C., HAASS, 
C. & EDBAUER, D. 2013b. The C9orf72 GGGGCC repeat is translated into aggregating 
dipeptide-repeat proteins in FTLD/ALS. Science, 339, 1335-8. 
MURRAY, L. M., TALBOT, K. & GILLINGWATER, T. H. 2010. Review: neuromuscular 
synaptic vulnerability in motor neurone disease: amyotrophic lateral sclerosis and spinal 
muscular atrophy. Neuropathol Appl Neurobiol, 36, 133-56. 
O'ROURKE, J. G., BOGDANIK, L., MUHAMMAD, A. K., GENDRON, T. F., KIM, K. J., 
AUSTIN, A., CADY, J., LIU, E. Y., ZARROW, J., GRANT, S., HO, R., BELL, S., 
CARMONA, S., SIMPKINSON, M., LALL, D., WU, K., DAUGHRITY, L., DICKSON, D. 
W., HARMS, M. B., PETRUCELLI, L., LEE, E. B., LUTZ, C. M. & BALOH, R. H. 2015. 
C9orf72 BAC Transgenic Mice Display Typical Pathologic Features of ALS/FTD. Neuron, 
88, 892-901. 
34 
 
O'ROURKE, J. G., BOGDANIK, L., YANEZ, A., LALL, D., WOLF, A. J., MUHAMMAD, 
A. K., HO, R., CARMONA, S., VIT, J. P., ZARROW, J., KIM, K. J., BELL, S., HARMS, 
M. B., MILLER, T. M., DANGLER, C. A., UNDERHILL, D. M., GOODRIDGE, H. S., 
LUTZ, C. M. & BALOH, R. H. 2016. C9orf72 is required for proper macrophage and 
microglial function in mice. Science, 351, 1324-9. 
PETERS, O. M., CABRERA, G. T., TRAN, H., GENDRON, T. F., MCKEON, J. E., 
METTERVILLE, J., WEISS, A., WIGHTMAN, N., SALAMEH, J., KIM, J., SUN, H., 
BOYLAN, K. B., DICKSON, D., KENNEDY, Z., LIN, Z., ZHANG, Y. J., DAUGHRITY, 
L., JUNG, C., GAO, F. B., SAPP, P. C., HORVITZ, H. R., BOSCO, D. A., BROWN, S. P., 
DE JONG, P., PETRUCELLI, L., MUELLER, C. & BROWN, R. H., JR. 2015. Human 
C9ORF72 Hexanucleotide Expansion Reproduces RNA Foci and Dipeptide Repeat Proteins 
but Not Neurodegeneration in BAC Transgenic Mice. Neuron, 88, 902-9. 
PLETNIKOVA, O., SLOANE, K. L., RENTON, A. E., TRAYNOR, B. J., CRAIN, B. J., 
REID, T., ZU, T., RANUM, L. P., TRONCOSO, J. C., RABINS, P. V. & ONYIKE, C. U. 
2014. Hippocampal sclerosis dementia with the C9ORF72 hexanucleotide repeat expansion. 
Neurobiol Aging, 35, 2419.e17-21. 
POWIS, R. A., KARYKA, E., BOYD, P., COME, J., JONES, R. A., ZHENG, Y., 
SZUNYOGOVA, E., GROEN, E. J., HUNTER, G., THOMSON, D., WISHART, T. M., 
BECKER, C. G., PARSON, S. H., MARTINAT, C., AZZOUZ, M. & GILLINGWATER, T. 
H. 2016. Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy. JCI 
Insight, 1, e87908. 
PUJADAS, L., ROSSI, D., ANDRÉS, R., TEIXEIRA, C. M., SERRA-VIDAL, B., 
PARCERISAS, A., MALDONADO, R., GIRALT, E., CARULLA, N. & SORIANO, E. 
2014. Reelin delays amyloid-beta fibril formation and rescues cognitive deficits in a model of 
Alzheimer's disease. Nat Commun, 5, 3443. 
RENTON, A. E., CHIO, A. & TRAYNOR, B. J. 2014. State of play in amyotrophic lateral 
sclerosis genetics. Nat Neurosci, 17, 17-23. 
RENTON, A. E., MAJOUNIE, E., WAITE, A., SIMON-SANCHEZ, J., ROLLINSON, S., 
GIBBS, J. R., SCHYMICK, J. C., LAAKSOVIRTA, H., VAN SWIETEN, J. C., 
MYLLYKANGAS, L., KALIMO, H., PAETAU, A., ABRAMZON, Y., REMES, A. M., 
KAGANOVICH, A., SCHOLZ, S. W., DUCKWORTH, J., DING, J., HARMER, D. W., 
HERNANDEZ, D. G., JOHNSON, J. O., MOK, K., RYTEN, M., TRABZUNI, D., 
GUERREIRO, R. J., ORRELL, R. W., NEAL, J., MURRAY, A., PEARSON, J., JANSEN, I. 
E., SONDERVAN, D., SEELAAR, H., BLAKE, D., YOUNG, K., HALLIWELL, N., 
CALLISTER, J. B., TOULSON, G., RICHARDSON, A., GERHARD, A., SNOWDEN, J., 
MANN, D., NEARY, D., NALLS, M. A., PEURALINNA, T., JANSSON, L., ISOVIITA, V. 
M., KAIVORINNE, A. L., HOLTTA-VUORI, M., IKONEN, E., SULKAVA, R., 
BENATAR, M., WUU, J., CHIO, A., RESTAGNO, G., BORGHERO, G., SABATELLI, M., 
CONSORTIUM, I., HECKERMAN, D., ROGAEVA, E., ZINMAN, L., ROTHSTEIN, J. D., 
SENDTNER, M., DREPPER, C., EICHLER, E. E., ALKAN, C., ABDULLAEV, Z., PACK, 
S. D., DUTRA, A., PAK, E., HARDY, J., SINGLETON, A., WILLIAMS, N. M., 
HEUTINK, P., PICKERING-BROWN, S., MORRIS, H. R., TIENARI, P. J. & TRAYNOR, 
35 
 
B. J. 2011. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 
9p21-linked ALS-FTD. Neuron, 72, 257-68. 
SCHLUDI, M. H., MAY, S., GRASSER, F. A., RENTZSCH, K., KREMMER, E., KUPPER, 
C., KLOPSTOCK, T., GERMAN CONSORTIUM FOR FRONTOTEMPORAL LOBAR, D., 
BAVARIAN BRAIN BANKING, A., ARZBERGER, T. & EDBAUER, D. 2015. 
Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases 
suggests link to transcriptional silencing. Acta Neuropathol, 130, 537-55. 
TRAN, H., ALMEIDA, S., MOORE, J., GENDRON, T. F., CHALASANI, U., LU, Y., DU, 
X., NICKERSON, J. A., PETRUCELLI, L., WENG, Z. & GAO, F. B. 2015. Differential 
Toxicity of Nuclear RNA Foci versus Dipeptide Repeat Proteins in a Drosophila Model of 
C9ORF72 FTD/ALS. Neuron, 87, 1207-14. 
TROMMSDORFF, M., GOTTHARDT, M., HIESBERGER, T., SHELTON, J., 
STOCKINGER, W., NIMPF, J., HAMMER, R. E., RICHARDSON, J. A. & HERZ, J. 1999. 
Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL 
receptor and ApoE receptor 2. Cell, 97, 689-701. 
TURNEY, S. G., CULICAN, S. M. & LICHTMAN, J. W. 1996. A quantitative fluorescence-
imaging technique for studying acetylcholine receptor turnover at neuromuscular junctions in 
living animals. J Neurosci Methods, 64, 199-208. 
WISHART, T. M., MUTSAERS, C. A., RIESSLAND, M., REIMER, M. M., HUNTER, G., 
HANNAM, M. L., EATON, S. L., FULLER, H. R., ROCHE, S. L., SOMERS, E., MORSE, 
R., YOUNG, P. J., LAMONT, D. J., HAMMERSCHMIDT, M., JOSHI, A., HOHENSTEIN, 
P., MORRIS, G. E., PARSON, S. H., SKEHEL, P. A., BECKER, T., ROBINSON, I. M., 
BECKER, C. G., WIRTH, B. & GILLINGWATER, T. H. 2014. Dysregulation of ubiquitin 
homeostasis and beta-catenin signaling promote spinal muscular atrophy. J Clin Invest, 124, 
1821-34. 
ZHANG, K., DONNELLY, C. J., HAEUSLER, A. R., GRIMA, J. C., MACHAMER, J. B., 
STEINWALD, P., DALEY, E. L., MILLER, S. J., CUNNINGHAM, K. M., VIDENSKY, S., 
GUPTA, S., THOMAS, M. A., HONG, I., CHIU, S. L., HUGANIR, R. L., OSTROW, L. W., 
MATUNIS, M. J., WANG, J., SATTLER, R., LLOYD, T. E. & ROTHSTEIN, J. D. 2015. 
The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature, 525, 56-61. 
ZU, T., GIBBENS, B., DOTY, N. S., GOMES-PEREIRA, M., HUGUET, A., STONE, M. 
D., MARGOLIS, J., PETERSON, M., MARKOWSKI, T. W., INGRAM, M. A., NAN, Z., 
FORSTER, C., LOW, W. C., SCHOSER, B., SOMIA, N. V., CLARK, H. B., 
SCHMECHEL, S., BITTERMAN, P. B., GOURDON, G., SWANSON, M. S., MOSELEY, 
M. & RANUM, L. P. 2011. Non-ATG-initiated translation directed by microsatellite 
expansions. Proc Natl Acad Sci U S A, 108, 260-5. 
 
Figure 1
A
AAV9-(G4C2)
10
AAV9-(G4C2)
102 ITR
ITRITR
ITR
CMV
CMV (G4C2)10-17
(G4C2)10
(G4C2)10-17
GTCGAC
GTCGAC
CTCGAC
TCGAC CTCGAC][ 4
10
10
2-r
ep
ea
t 10
10
2-r
ep
ea
t 10
10
2-r
ep
ea
t
0
500
1000
1500
2000
2500
CTX                CB                   HC
FO
C
I p
er
 m
m
2
HRE-10
HRE-102
NS
NS
  
NS
B C D
F
HC CTX
CB
SC
E
*
SC
Figure 2
DG
CA3
CA1
DG CA
3
CA
1
0
50
100
150
200
250250
200
150
100
  50
  G        C 3        C 1
)
mµ( ssenkci hT
10
102
NS
NS
*
p62
GAPDH
10 102
102
polyGA
102
63 kD
50 kD
A B
poly(GA)
C D E
63 kD
50 kD
25 kD
10   10   10   102  102  102
25 kD
Triton soluble Triton insoluble
63 kD
50 kD
Tubulin Tubulin
poly(GA)
  10   10    10   102  102  102
F
GAPDH
Cleaved caspase-3
10
10
2-r
ep
ea
t
0
1
2
3
4
5
HRE-10
HRE-102
G H
HRE-10    HRE-102       
*    5
    4
    3
    2
    1
P
R
AP devael
C 
+  
m
m/sll ec(     
2 )clePARP
1        2       3       1      2       3
HRE-10 HRE-102
1        2        3        1      2         3
HRE-10     HRE-102
polyGA
HRE-102HRE-10
clePARP
PB
S 
10
-RE
P 
10
2 R
EP
 
0
20
40
60
Figure 3
sJ
M
N laci gol oht aP f o 
%
A B
C
100%
PBS 102 6
4
2
  
NS
NS
NS
1P
BS
10-
rep
 
10
2-r
ep
0.4
0.6
0.8
1.0
1.2
**
S      HRE-10   HRE-102
NS
*
1.2
nae
M dezil a
mr o
N
 ecnecser oul F   
D
1.0
0.8
0.6
PBS              HRE-10          HRE-102
95% 80%
PBS     HRE-10    HR -102
2H3/SV2
AChR
PBS HRE-10 HRE-102
Figure 4
10 HRE
102 HRE
Fro
nt
Hin
d
0.00
0.05
0.10
0.15
0.200.20
0.15
0.10
0.05
     
Front                 ind
* *
A
B
Fro
n t
Hin
d
0
10
20
30
ront           Hind
30
20
10
*
NS
Stand BOS
Dia
go
n thr
eDiagonal               Three
C
Rig
ht Le
ft
0.0
0.5
1.0
1.5
2.0
 Right                 Left
*2.0
1.5
1.0
0.5
DxednI yal pS b
mil dni
H 0  re p
10
2 r
e p
0
100
200
300
400400
300
10
20
10 HRE       1 2 HRE
NS
10 HRE
102 HRE
10 HRE
102 HRE
al e
0
20
40
60
80
*
**
Support
  80
  60
  4
  2
10 HRE
102 HRE
ni
m 01 ni sgnissorc fo #
10
-re
p  R
ig h
t
10
-re
p L
e ft
10
2-r
e p
 R
igh
t
10
2-r
e p
 Le
ft
0
5
10
15
)
m
m( ht di
W
)s( e
mi T
 noit ar ud evit al e
R   
)s( t cat noc ecafr us f o
)s( e
mi T
)s( e
mi T
NS NS NS*
10
-re
p  R
ig h
t
10
-re
p  N
ew
10
2-r
e p
 R
igh
t
10
2-r
e p
 N
ew
0
5
10
15
Familiarization Test
1 tcejb
O
1 t cej b
O
2 t cej b
O
2 t cej b
O
1 t cej b
O
1 t cej b
O
3 t cej b
O
3 t cej b
O
  15
  10
    5
10 HRE
102 HRE
  15
  10
    5
NS
